Implantable cardioverter-defibrillator therapy in primary versus secondary prevention: Reliable prediction of appropriate therapies and mortality is still an unmet need

Tsuji, Yukiomi; Dobrev, Dobromir

doi:10.1016/j.ijcha.2021.100740

Cited by 1 publication

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Low LVEF and ICDs placed for primary prevention are both well-established predictors of ICD shocks on their own. 26,27 Therefore, the lack of significant difference in these subgroups despite addition of combined amiodarone therapy further supports our primary outcome result.…”

Section: Discussionsupporting

confidence: 75%

Amiodarone and β‐blocker combination therapy versus β‐blocker monotherapy for ICD shock prevention: A meta‐analysis

Yazdi,

Moustafa,

Nawras

et al. 2024

Pacing Clinical Electrophis

View full text Add to dashboard Cite

While implantable cardioverter‐defibrillator (ICD) shocks are a lifesaving therapy, they can negatively affect the patient's quality of life. Amiodarone is commonly combined with β‐blockers (BB) in ICD recipients. However, this combination therapy's efficacy in preventing shocks compared to standard BB monotherapy is not well studied. The aim of this systematic review and meta‐analysis is to determine if combined amiodarone and BB therapy improves prevention of ICD shock delivery compared to BB monotherapy. We performed a comprehensive literature search using PubMed, Cochrane, and Web of Science databases, for studies that assess the impact of amiodarone and BB versus BB monotherapy in patients with an ICD. The primary outcome was a total number of ICD shocks delivered by the end of the study period. Four studies: three retrospective studies and one randomized controlled trial (RCT), with a total of 5818 patients with ICDs, were included in the analysis. Follow‐up periods ranged from 1 to 5 years. The combined amiodarone and BB group was not associated with a significantly lower number of ICD shocks compared to the BB monotherapy group (OR, 0.76; 95% CI, 0.44‐1.31; P = .32). A combination therapy of amiodarone and BB was not associated with any further reduction in ICD shocks, hospitalizations, or mortality. Additional RCTs are recommended to further validate our findings.

show abstract

Section: Discussionsupporting

confidence: 75%